EUVIMEDEUVIMED entdecken
Crossref

2847-LB: PT403, a Once-Monthly Long-Acting Semaglutide: Preclinical Efficacy and Interim Safety and Tolerability in Healthy Subjects

MYUNG-JOO CHOI, HYUNJU JEONG, SU HEE KIM, YOUNGHEE SHIN, JIHYANG LEE, SUNGWON W. KIM, SEUNG-GU CHANG, HOIL CHOI

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2847-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MYUNG-JOO CHOI und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: GLP-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity but frequent injections may limit adherence. PT403 is a long-acting semaglutide formulation based on biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres designed for once-monthly administration. This study evaluated the pharmacological efficacy, safety, and tolerability of PT403 and explored its translational development potential as a once-monthly semaglutide formulation.

Methods

PT403 was formulated by encapsulating semaglutide in biodegradable PLGA microspheres using ultrasonic spray-drying for sustained release. Preclinical efficacy was evaluated in a high-fat diet-induced obesity (DIO) mouse model with dosing regimens maintaining equivalent daily exposure while varying injection intervals. In a randomized, open-label pilot study, 16 healthy adults received either weekly semaglutide (0.5 mg once weekly for four weeks; n=8) or a single subcutaneous dose of PT403 (4 mg; n=8). Safety and adverse events were monitored for 57 days.

Results

In the DIO mouse model, PT403 demonstrated sustained body weight reduction. A -30% reduction at week 4 was achieved in the PT403 Q2W and Q3W groups, whereas semaglutide QD and Q3D groups did not reach this target. In the pilot study, 69 adverse events were reported (PT403: 27; reference: 33). Therapeutic intervention was required for 45.5% of ADRs with weekly semaglutide vs 29.6% with PT403. Nausea and vomiting occurred with weekly semaglutide but not with PT403. PT403 ADRs were mild injection-site reactions and decreased appetite. No serious adverse events were reported.

Conclusion

PT403 demonstrated sustained pharmacodynamic efficacy in preclinical models and favorable safety and tolerability in a pilot study. These findings suggest that PT403 has the potential to be developed as a differentiated long-acting GLP-1RA formulation that may reduce injection burden, improve tolerability, and enhance long-term treatment adherence. Disclosure M. Choi: None. H. Jeong: None. S. Kim: Employee; Current; Peptron. Y. Shin: None. J. Lee: None. S.W. Kim: None. S. Chang: None. H. Choi: None.

Zitieren

APA

CHOI, M., JEONG, H., KIM, S. H., SHIN, Y., LEE, J., KIM, S. W., CHANG, S., & CHOI, H. (2026). 2847-LB: PT403, a Once-Monthly Long-Acting Semaglutide: Preclinical Efficacy and Interim Safety and Tolerability in Healthy Subjects. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2847-lb

Vancouver

CHOI M, JEONG H, KIM SH, SHIN Y, LEE J, KIM SW, et al. 2847-LB: PT403, a Once-Monthly Long-Acting Semaglutide: Preclinical Efficacy and Interim Safety and Tolerability in Healthy Subjects. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2847-lb

BibTeX
@article{CHOI2026,
  author = {CHOI, MYUNG-JOO and JEONG, HYUNJU and KIM, SU HEE and SHIN, YOUNGHEE and LEE, JIHYANG and KIM, SUNGWON W. and CHANG, SEUNG-GU and CHOI, HOIL},
  title = {2847-LB: PT403, a Once-Monthly Long-Acting Semaglutide: Preclinical Efficacy and Interim Safety and Tolerability in Healthy Subjects},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2847-lb}
}
Kostenlos starten →